A61K 51/0463
Having six-membered rings with at least one nitrogen and one oxygen as
Official title: {having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines}
A61K51/0463 (Having six-membered rings with at least one nitrogen and one oxygen as) appears on 48 US grants and 76 published applications in this corpus.
Search patents in A61K- Granted patents
- 48
- Published applications
- 76
- Assignees
- 55
- Inventors
- 256
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 2 |
| 2003 | 1 | 2 |
| 2004 | 0 | 2 |
| 2005 | 2 | 4 |
| 2006 | 0 | 2 |
| 2007 | 1 | 1 |
| 2008 | 3 | 2 |
| 2009 | 1 | 4 |
| 2010 | 1 | 4 |
| 2011 | 1 | 4 |
| 2012 | 1 | 3 |
| 2013 | 2 | 2 |
| 2014 | 0 | 3 |
| 2015 | 0 | 1 |
| 2016 | 3 | 4 |
| 2017 | 3 | 6 |
| 2018 | 2 | 4 |
| 2019 | 4 | 1 |
| 2020 | 3 | 3 |
| 2021 | 2 | 2 |
| 2022 | 4 | 8 |
| 2023 | 0 | 3 |
| 2024 | 3 | 4 |
| 2025 | 2 | 4 |
| 2026 | 4 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer22 Sep 2026US 12,741,964 B2Cornell University
- Small molecules for dual function positron emission tomography (PET) and cell suicide switches4 Aug 2026US 12,697,403 B2The Trustees of the University of Pennsylvania
- Heterocyclic compounds and imaging agents for imaging Huntington protein17 Feb 2026US 12,551,580 B2CHDI Foundation, Inc.
- Compounds for diagnosis17 Feb 2026US 12,552,800 B2AC Immune SA
- Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer25 Mar 2025US 12,258,339 B2Cornell University
- Follicle-stimulating hormone receptor (fshr) targeted therapeutics and uses thereof21 May 2026US 2026/0137819 A1Radionetics Oncology, Inc.
- Method for preparing an [18f] radiolabelled compound with low water content during labelling step9 Oct 2025US 2025/0312494 A1Ge Healthcare Limited
- Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer3 Jul 2025US 2025/0214985 A1Cornell University
- Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer22 May 2025US 2025/0163040 A1Cornell University
- Aromatic vinyl compound, metal complex thereof, and preparation method therefor and use thereof6 Mar 2025US 2025/0073358 A1Shanghai Maxinovel Pharmaceuticals Co., Ltd.
Most cited
By later US patents
- Diagnostic radiopharmaceuticals for localization in target tissues exhibiting a regional pH shift relative to surrounding tissues29US 4,363,793 AState University of New York · 1982
- Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent21US 6,117,855 AMerck Sharp & Dohme Corp. · 2000
- Treatment of depression and anxiety with fluoxetine and an NK-1 receptor antagonist20US 6,319,953 B1Merck Sharp & Dohme Corp. · 2001
- Heterocyclic compounds for cancer imaging and treatment and methods for their use11US 10,654,811 B2British Columbia Cancer Agency Branch · 2020
- Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors10US 6,911,444 B2Janssen Pharmaceutics, N.V. · 2005